Jana Fassunke - Concepedia

Author

Jana Fassunke

University Hospital Cologne ORCID

Also Known As

Fassunke, Jana, J Fassunke, J. Fassunke, JANA FASSUNKE, Jana Fassunke

114

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

University Hospital Cologne University of Cologne Krankenhaus Bethanien University of Bonn Johanniter-Krankenhaus Bonn

About

Jana Fassunke is an author at University Hospital Cologne specializing in medicine, pathology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	22	855
2	Health Sciences	5	5	163
3	Engineering	4	4	44
4	Social Sciences	2	2	48
5	Public Health	1	1	10

Jana Fassunke

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors Sandra Ortiz‐Cuaran, Matthias Scheffler, Dennis Plenker, Clinical Cancer Research	2016	259
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways Matthias Scheffler, Michaela A. Ihle, Rebecca Hein, Journal of Thoracic Oncology	2018	247
Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAFmutations Michaela A. Ihle, Jana Fassunke, Katharina König, BMC Cancer	2014	246
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer Anna Kron, Christina Alidousty, Matthias Scheffler, Annals of Oncology	2018	207
<i>MET</i> Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung Hans‐Ulrich Schildhaus, Anne M. Schultheis, Josef Rüschoff, Clinical Cancer Research	2014	187
Clinical and Pathological Characteristics of <i>KEAP1</i> - and <i>NFE2L2</i> -Mutated Non–Small Cell Lung Carcinoma (NSCLC) Rieke Frank, Matthias Scheffler, Sabine Merkelbach‐Bruse, Clinical Cancer Research	2018	161
Tumor recurrence and malignant progression of gangliogliomas Michael Majores, Marec von Lehe, Jana Fassunke, Cancer	2008	155
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors Jana Fassunke, Fabienne Müller, Marina Keul, Nature Communications	2018	139
<i>PIK3CA</i> mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies Matthias Scheffler, Marc Bos, Masyar Gardizi, Oncotarget	2014	137
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial Sebastian Michels, Bartomeu Massutí, Hans‐Ulrich Schildhaus, Journal of Thoracic Oncology OncologyCancer ManagementPathologyBronchial NeoplasmCancer Treatment	2019	128

Page 1